CLDN18 and neoplasm: Furthermore, CLDN18.2 therapeutic antibody IMAB362 has demonstrated remarkable efficacy in CLDN18.2‐positive and HER2‐negative GCs.[21, 22] Enhancing the affinity and specificity of CLDN18.2 monoclonal antibodies is critical for accurately differentiating between various CLDN18 subtypes within the complex tumor microenvironment.